SLC25A1 and steatosis: Inhibition of CiC/SLC25A1 with a specific inhibitor compound CTPI-2 (2-((4-chloro-3-nitrophenyl)sulfonamido)benzoic acid) (Figure 2) reverses steatosis, glucose intolerance, and inflammation in HFD-fed mice [87].